Compare CYTK & KNSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYTK | KNSL |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.8B |
| IPO Year | 2004 | 2016 |
| Metric | CYTK | KNSL |
|---|---|---|
| Price | $62.51 | $397.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 10 |
| Target Price | $78.94 | ★ $483.78 |
| AVG Volume (30 Days) | ★ 1.7M | 267.0K |
| Earning Date | 11-05-2025 | 10-23-2025 |
| Dividend Yield | N/A | ★ 0.17% |
| EPS Growth | N/A | ★ 16.09 |
| EPS | N/A | ★ 20.35 |
| Revenue | $87,211,000.00 | ★ $1,802,839,000.00 |
| Revenue This Year | $361.33 | $19.56 |
| Revenue Next Year | $65.14 | $7.74 |
| P/E Ratio | ★ N/A | $19.62 |
| Revenue Growth | ★ 2609.26 | 18.10 |
| 52 Week Low | $29.31 | $349.00 |
| 52 Week High | $69.33 | $512.76 |
| Indicator | CYTK | KNSL |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 56.15 |
| Support Level | $59.37 | $377.46 |
| Resistance Level | $63.80 | $401.15 |
| Average True Range (ATR) | 2.56 | 11.11 |
| MACD | -0.44 | 4.34 |
| Stochastic Oscillator | 42.46 | 94.90 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.